| Matthew J Hubbard, DO | |
|
301 Fisher St, Keesler Afb, MS 39534 | |
| (228) 376-3629 | |
| Not Available |
| Full Name | Matthew J Hubbard |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 11 Years |
| Location | 301 Fisher St, Keesler Afb, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528401015 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 1304 (Nebraska) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dixie Regional Medical Center | St george, UT | Hospital |
| Cedar City Hospital | Cedar city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Inhibitex, Inc. today reported the completion of its previously announced $23 million private placement of common stock and warrants. Investors in the private placement purchased units, each consisting of one share of common stock and a warrant to purchase .45 of a share of common stock, at a purchase price of $1.28 per unit, which is equal to the consolidated closing bid price of the common stock as reported on the NASDAQ Capital Market for October 22, 2009, plus $0.06.
A new study has found that patients with dementia who are in hospital and in pain are often unable to communicate that they are in pain.
The disease consists of a production deficit of Alpha-1 antitrypsin, which is produced in the liver. The main role of this protein is to protect the lungs from degradation or inflammation caused by infections that attach lung tissue, as well as from external agents such a tobacco or pollution.
Rhode Island Hospital has received a grant for more than $1.5 million from the National Institute of Mental Health (NIMH) for a 5-year study on treatment for Body Dysmorphic Disorder (BDD). Led by Katharine A. Phillips, M.D., director of the BDD Program at Rhode Island Hospital and an internationally known expert in BDD, the study will examine the effectiveness of cognitive behavioral therapy versus supportive psychotherapy for the treatment of people with BDD.
Ugandan children who received the combination therapy of artemether-lumefantrine experienced a lower rate of treatment failure compared to other combination therapies, according to a study in the May 23/30 issue of JAMA , a theme issue on malaria.
› Verified 4 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Inhibitex, Inc. today reported the completion of its previously announced $23 million private placement of common stock and warrants. Investors in the private placement purchased units, each consisting of one share of common stock and a warrant to purchase .45 of a share of common stock, at a purchase price of $1.28 per unit, which is equal to the consolidated closing bid price of the common stock as reported on the NASDAQ Capital Market for October 22, 2009, plus $0.06.
A new study has found that patients with dementia who are in hospital and in pain are often unable to communicate that they are in pain.
The disease consists of a production deficit of Alpha-1 antitrypsin, which is produced in the liver. The main role of this protein is to protect the lungs from degradation or inflammation caused by infections that attach lung tissue, as well as from external agents such a tobacco or pollution.
Rhode Island Hospital has received a grant for more than $1.5 million from the National Institute of Mental Health (NIMH) for a 5-year study on treatment for Body Dysmorphic Disorder (BDD). Led by Katharine A. Phillips, M.D., director of the BDD Program at Rhode Island Hospital and an internationally known expert in BDD, the study will examine the effectiveness of cognitive behavioral therapy versus supportive psychotherapy for the treatment of people with BDD.
Ugandan children who received the combination therapy of artemether-lumefantrine experienced a lower rate of treatment failure compared to other combination therapies, according to a study in the May 23/30 issue of JAMA , a theme issue on malaria.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew J Hubbard, DO 301 Fisher St, Keesler Afb, MS 39534-2508 Ph: (228) 376-3629 | Matthew J Hubbard, DO 301 Fisher St, Keesler Afb, MS 39534 Ph: (228) 376-3629 |
News Archive
Inhibitex, Inc. today reported the completion of its previously announced $23 million private placement of common stock and warrants. Investors in the private placement purchased units, each consisting of one share of common stock and a warrant to purchase .45 of a share of common stock, at a purchase price of $1.28 per unit, which is equal to the consolidated closing bid price of the common stock as reported on the NASDAQ Capital Market for October 22, 2009, plus $0.06.
A new study has found that patients with dementia who are in hospital and in pain are often unable to communicate that they are in pain.
The disease consists of a production deficit of Alpha-1 antitrypsin, which is produced in the liver. The main role of this protein is to protect the lungs from degradation or inflammation caused by infections that attach lung tissue, as well as from external agents such a tobacco or pollution.
Rhode Island Hospital has received a grant for more than $1.5 million from the National Institute of Mental Health (NIMH) for a 5-year study on treatment for Body Dysmorphic Disorder (BDD). Led by Katharine A. Phillips, M.D., director of the BDD Program at Rhode Island Hospital and an internationally known expert in BDD, the study will examine the effectiveness of cognitive behavioral therapy versus supportive psychotherapy for the treatment of people with BDD.
Ugandan children who received the combination therapy of artemether-lumefantrine experienced a lower rate of treatment failure compared to other combination therapies, according to a study in the May 23/30 issue of JAMA , a theme issue on malaria.
› Verified 4 days ago
Audra Cochran, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 301 Fisher St, Keesler Afb, MS 39534 Phone: 228-376-3082 | |
Ms. Melinda Marie Auxier, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 301 Fisher St, 88 Mdos/sgom, Keesler Afb, MS 39534 Phone: 228-376-0576 | |
Brycen Wilson, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 81 Mdss/gme, 301 Fisher Street Rm 1g123, Keesler Afb, MS 39534 Phone: 865-806-5088 | |
Frank David Russo, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 301 Fisher St, Keesler Afb, MS 39534 Phone: 228-376-3807 Fax: 228-376-0105 | |
Dr. Matthew Christopher Hann, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 301 Fisher St, Keesler Afb, MS 39534 Phone: 228-342-6178 | |
Stuart Thomas Wood, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 301 Fisher St, Keesler Afb, MS 39534 Phone: 228-376-3551 |